ReviewCell communication and signaling : CCS2026
Macrophages in post-chemoradiotherapy hematopoietic injury: a double-edged sword.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Radiotherapy and chemotherapy are primary cancer treatments, yet hematopoietic damage induced by these therapies is increasingly prevalent. Under physiological conditions, macrophages serve as key regulators of hematopoietic stem cells (HSCs) and the hematopoietic microenvironment. Through bidirectional regulatory mechanisms driven by functional heterogeneity among macrophage subtypes, they dynamically modulate hematopoiesis. This includes maintaining HSCs quiescence and mobilization, ensuring HSCs quality control, regulating HSCs localization, and balancing inflammatory responses with microenvironmental remodeling within the hematopoietic niche. Following chemoradiation therapy, macrophages exert bidirectional effects on hematopoietic damage. On one hand, they exacerbate injury by intensifying HSCs damage, disrupting hematopoietic microenvironment homeostasis, and inducing myeloid bias. On the other hand, they support hematopoietic recovery through mechanisms such as maintaining HSCs function and promoting hematopoietic niche reconstruction. Furthermore, we summarize the application potential of natural products and small molecules based on macrophage regulation in improving hematopoietic damage after chemoradiotherapy, aiming to provide new insights for developing clinical treatment strategies. Future research should further elucidate the molecular mechanisms of macrophage regulation of hematopoiesis after chemoradiotherapy and explore precision therapeutic strategies targeting macrophages to optimize prevention and treatment protocols for bone marrow hematopoietic damage following chemoradiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.